Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [21] Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
    Pegram, MD
    Pienkowski, T
    Northfelt, DW
    Eiermann, W
    Patel, R
    Fumoleau, P
    Quan, E
    Crown, J
    Toppmeyer, D
    Smylie, M
    Riva, A
    Blitz, S
    Press, MF
    Reese, D
    Lindsay, MA
    Slamon, DJ
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (10): : 759 - 769
  • [22] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Heo, Young-A
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2019, 14 (06) : 749 - 758
  • [23] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Young-A Heo
    Yahiya Y. Syed
    Targeted Oncology, 2019, 14 : 749 - 758
  • [24] Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer
    Olsen, Jens
    Jensen, Kenneth Forsstrom
    Olesen, Daniel Sloth
    Knoop, Ann
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (05) : 411 - 419
  • [25] Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study
    Kuemmel, Sherko
    Tondini, Carlo A.
    Abraham, Jacinta
    Nowecki, Zbigniew
    Itrych, Bartosz
    Hitre, Erika
    Karaszewska, Boguslawa
    Juarez, Alejandro
    Morales-Vasquez, Flavia
    Perez Garcia, Jose Manuel
    Cardona-Huerta, Servando
    Benyunes, Mark
    Restuccia, Eleonora
    Knott, Adam
    Monturus, Estefania
    Sequi, Marco
    Martin, Miguel
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study
    Hong, Ruoxi
    Xia, Wen
    Wang, Liye
    Lee, Kaping
    Lu, Qianyi
    Jiang, Kuikui
    Li, Shengfeng
    Yu, Jinquan
    Wei, Jin
    Tang, Weijia
    Zhou, Danyang
    An, Xin
    Huang, Jiajia
    Xue, Cong
    Bi, Xiwen
    Shi, Yanxia
    Yuan, Zhongyu
    Xu, Fei
    Wang, Shusen
    CANCER COMMUNICATIONS, 2021, 41 (02) : 171 - 182
  • [27] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [28] MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
    Strickler, J.
    Ng, K.
    Cercek, A.
    Fountzilas, C.
    Sanchez, F.
    Hubbard, J.
    Wu, C.
    Stecher, M.
    Walker, L. N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S460 - S461
  • [29] Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
    Sherko Kuemmel
    Carlo A. Tondini
    Jacinta Abraham
    Zbigniew Nowecki
    Bartosz Itrych
    Erika Hitre
    Bogusława Karaszewska
    Alejandro Juárez-Ramiro
    Flavia Morales-Vásquez
    Jose Manuel Pérez-García
    Servando Cardona-Huerta
    Estefania Monturus
    Marco Sequi
    Eleonora Restuccia
    Mark Benyunes
    Miguel Martín
    Breast Cancer Research and Treatment, 2021, 187 : 467 - 476
  • [30] Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
    Kuemmel, Sherko
    Tondini, Carlo A.
    Abraham, Jacinta
    Nowecki, Zbigniew
    Itrych, Bartosz
    Hitre, Erika
    Karaszewska, Boguslawa
    Juarez-Ramiro, Alejandro
    Morales-Vasquez, Flavia
    Perez-Garcia, Jose Manuel
    Cardona-Huerta, Servando
    Monturus, Estefania
    Sequi, Marco
    Restuccia, Eleonora
    Benyunes, Mark
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (02) : 467 - 476
12345